Correlation of the Ga-68-bombesin Analog Ga-68-BZH3 with Receptors Expression in Gliomas As Measured by Quantitative Dynamic Positron Emission Tomography (dPET) and Gene Arrays

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2011 Jul 12

PMID 21744169

Citations 9

Authors

Ludwig G Strauss

Dirk Koczan

Marcel Seiz

Jochen Tuettenberg

Kirsten Schmieder

Leyun Pan

Caixia Cheng

Antonia Dimitrakopoulou-Strauss

Affiliations

Soon will be listed here.

Abstract

Purpose: The kinetics of Ga-68-BZH3, a Ga-68-bombesin analog, was compared to molecular biological data obtained from gene arrays in seven patients with a recurrent glioma. The primary aim of this study was the correlation of receptor expression and tracer kinetics.

Procedures: Dynamic positron emission tomography studies were performed and the data were analyzed by a volume-of-interest technique using a two-tissue compartment model as well as a non-compartment model. Gene array data were obtained from gene array analysis of tumor tissue samples.

Results: The correlation analysis revealed a significant nonlinear correlation of r = 0.89 (p < 0.03) for k1 and BB(2) (gastrin-releasing peptide receptor). BB(1) and BB(3) were not significantly correlated with k1. vb and k3 were not significantly correlated with the expression data of the receptors on the p < 0.05 level.

Conclusions: The parameter k1 is correlated with the expression of BB(2) based on gene array data. The quantitative analysis of the Ga-68-BZH3 kinetics can be used to predict the receptor expression of BB(2) in gliomas based on k1 of the compartment analysis. However, this study is limited to the expression data on the mRNA level and further studies are needed to assess the correlation of gene expression on the protein level.

Citing Articles

Synthesis and Preclinical Evaluation of a Bispecific PSMA-617/RM2 Heterodimer Targeting Prostate Cancer.

Liolios C, Bouziotis D, Sihver W, Schafer M, Lambrinidis G, Salvanou E ACS Med Chem Lett. 2024; 15(11):1970-1978.

PMID: 39563828 PMC: 11571012. DOI: 10.1021/acsmedchemlett.4c00324.

Imaging Properties and Tumor Targeting of Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients.

Gruber L, Decristoforo C, Uprimny C, Hohenberger P, Schoenberg S, Orlandi F Biomedicines. 2022; 10(11).

PMID: 36428467 PMC: 9687401. DOI: 10.3390/biomedicines10112899.

Radiolabeled PSMA Inhibitors.

Neels O, Kopka K, Liolios C, Afshar-Oromieh A Cancers (Basel). 2021; 13(24).

PMID: 34944875 PMC: 8699044. DOI: 10.3390/cancers13246255.

Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.

Moody T, Lee L, Ramos-Alvarez I, Iordanskaia T, Mantey S, Jensen R Front Endocrinol (Lausanne). 2021; 12:728088.

PMID: 34539578 PMC: 8441013. DOI: 10.3389/fendo.2021.728088.

Effect of the versatile bifunctional chelator AAZTA on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist.

Hofstetter M, Moon E, DAngelo F, Geissbuhler L, Alberts I, Afshar-Oromieh A EJNMMI Radiopharm Chem. 2020; 5(1):29.

PMID: 33258012 PMC: 7704979. DOI: 10.1186/s41181-020-00115-8.

References

Flores D, Meurer L, Uberti A, Macedo B, Lenz G, Brunetto A . Gastrin-releasing peptide receptor content in human glioma and normal brain. Brain Res Bull. 2010; 82(1-2):95-8. DOI: 10.1016/j.brainresbull.2010.02.014. View

Strauss L, Conti P . The applications of PET in clinical oncology. J Nucl Med. 1991; 32(4):623-48; discussion 649-50. View

PRADHAN T, Katsuno T, Taylor J, Kim S, Ryan R, Mantey S . Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J Pharmacol. 1998; 343(2-3):275-87. DOI: 10.1016/s0014-2999(97)01527-6. View

Strauss L . Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996; 23(10):1409-15. DOI: 10.1007/BF01367602. View

Strauss L, Dimitrakopoulou-Strauss A, Koczan D, Bernd L, Haberkorn U, Ewerbeck V . 18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med. 2004; 45(9):1528-35. View

Scopinaro F, De Vincentis G, Corazziari E, Massa R, Osti M, Pallotta N . Detection of colon cancer with 99mTc-labeled bombesin derivative (99mTc-leu13-BN1). Cancer Biother Radiopharm. 2004; 19(2):245-52. DOI: 10.1089/108497804323072020. View

Strauss L, Koczan D, Klippel S, Pan L, Cheng C, Willis S . Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors. J Nucl Med. 2008; 49(8):1238-44. DOI: 10.2967/jnumed.108.051599. View

Scopinaro F, De Vincentis G, Varvarigou A, Laurenti C, Iori F, Remediani S . 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging. 2003; 30(10):1378-82. DOI: 10.1007/s00259-003-1261-7. View

Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F, Koukouraki S, Macke H . Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET. Eur J Nucl Med Mol Imaging. 2006; 33(7):823-30. DOI: 10.1007/s00259-005-0063-5. View

10.

Koukouraki S, Strauss L, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N . Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006; 33(4):460-6. DOI: 10.1007/s00259-005-0006-1. View

11.

Dimitrakopoulou-Strauss A, Strauss L . The role of 18F-FLT in cancer imaging: does it really reflect proliferation?. Eur J Nucl Med Mol Imaging. 2008; 35(3):523-6. DOI: 10.1007/s00259-007-0679-8. View

12.

Seiz M, Dimitrakopoulou-Strauss A, Schubert G, Weinmann C, Strauss L, Eisenhut M . Differentiation between malignant transformation and tumour recurrence by (68)Ga-bombesin and (18)F-FDG-PET, in patients with low grade gliomas. Hell J Nucl Med. 2008; 11(3):149-52. View

13.

Strauss L, Pan L, Koczan D, Klippel S, Mikolajczyk K, Burger C . Fusion of positron emission tomography (PET) and gene array data: a new approach for the correlative analysis of molecular biological and clinical data. IEEE Trans Med Imaging. 2007; 26(6):804-12. DOI: 10.1109/TMI.2007.892645. View

14.

De Oliveira M, Cechim G, Braganhol E, Santos D, Meurer L, de Castro Jr C . Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. J Neurooncol. 2009; 93(2):191-201. DOI: 10.1007/s11060-008-9775-2. View

15.

Reubi J, Wenger S, Schmuckli-Maurer J, Schaer J, Gugger M . Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res. 2002; 8(4):1139-46. View

16.

Ohtake T, Kosaka N, Watanabe T, Yokoyama I, Moritan T, Masuo M . Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. J Nucl Med. 1991; 32(7):1432-8. View

17.

Schuhmacher J, Zhang H, Doll J, Macke H, Matys R, Hauser H . GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog. J Nucl Med. 2005; 46(4):691-9. View

18.

Bodei L, Pepe G, Paganelli G . Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci. 2010; 14(4):347-51. View

19.

Pascal L, True L, Campbell D, Deutsch E, Risk M, Coleman I . Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics. 2008; 9:246. PMC: 2413246. DOI: 10.1186/1471-2164-9-246. View

20.

Kang J, Ishola T, Baregamian N, Mourot J, Rychahou P, Evers B . Bombesin induces angiogenesis and neuroblastoma growth. Cancer Lett. 2007; 253(2):273-81. PMC: 2709810. DOI: 10.1016/j.canlet.2007.02.007. View